Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema

Immunotherapy

Volumn 6, Issue 5, 2014, Pages 533-551

  Bork, Konrad ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Berinert ; C1 esterase inhibitor; C1 INH; Complement system; Contact system; Hereditary angioedema; PdC1 INH concentrate; PnfC1 INH; Prophylaxis

Indexed keywords

AUTOANTIBODY; BCX 4161; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; DX 2930; ECALLANTIDE; ICATIBANT; KALLIKREIN INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ARTICLE; AUTOSOMAL DOMINANT DISORDER; DIZZINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FEVER; HEADACHE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INFUSION RELATED REACTION; MUSCLE SPASM; MYCOSIS; NANOFILTRATION; NAUSEA; PASTEURIZATION; PEDIATRICS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA; POSTMARKETING SURVEILLANCE; PREGNANT WOMAN; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; RASH; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; VIRUS TRANSMISSION; VOMITING; ANGIOEDEMAS, HEREDITARY; CHEMISTRY; PRACTICE GUIDELINE; PROCEDURES;

ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; PASTEURIZATION; PLASMA; PRACTICE GUIDELINES AS TOPIC;

EID: 84902119995     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.33     Document Type: Article

References (87)

1. Donaldson VH, Evans RR. A biochemical abnormality in herediatry angioneurotic edema: Absence of serum inhibitor of C' 1-esterase. Am. J. Med. 35, 37-44 (1963).
2. Agostoni A, Aygoren-Pursun E, Binkley KE et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 114, S51-S131 (2004).
3. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356(9225), 213-217 (2000).
4. Bork K. Hereditary angioedema with normal C1 inhibitor. Immunol. Allergy Clin. North Am. 33(4), 457-470 (2013).
5. HAEdb, C1 esterase inhibitor gene mutation database. http://hae.enzim.hu/ stat.php
6. Pappalardo E, Cicardi M, Duponchel C et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J. Allergy Clin. Immunol. 106(6), 1147-1154 (2000).
7. Bowen T, Cicardi M, Bork K et al. Hereditary angiodema. a current state-of-The-Art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann. Allergy Asthma Immunol. 100(1 Suppl. 2), S30-S40 (2008).
8. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: A broad review for clinicians. Arch. Intern. Med. 161(20), 2417-2429 (2001).
9. Davis AE 3rd. Hereditary angioedema: A current state-of-The-Art review, III: Mechanisms of hereditary angioedema. Ann. Allergy Asthma Immunol. 100(1 Suppl. 2), S7-S12 (2008).
10. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am. J. Med. 119(3), 267-274 (2006).
11. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch. Intern. Med. 163(10), 1229-1235 (2003).
12. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J. Allergy Clin. Immunol. 130(3), 692-697 (2012).
13. Bork K, Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: Assessment and clinical management. Eur. Ann. Allergy Clin. Immunol. 45(1), 7-16 (2013).
14. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am. J. Obstet. Gynecol. 203(2), e131-e137 (2010).
15. Bork K. Current management options for hereditary angioedema. Curr. Allergy Asthma Rep. 12(4), 273-280 (2012).
16. Bowen T, Cicardi M, Farkas H et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin. Immunol. 6(1), 24 (2010).
17. Lang DM, Aberer W, Bernstein JA et al. International consensus on hereditary and acquired angioedema. Ann. Allergy Asthma Immunol. 109(6), 395-402 (2012).
18. Cicardi M, Bork K, Caballero T et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency. consensus report of an International Working Group. Allergy 67(2), 147-157 (2012).
19. Craig T, Aygoren-Pursun E, Bork K et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 5(12), 182-199 (2012).
20. Longhurst HJ, Farkas H, Craig T et al. HAE international home therapy consensus document. Allergy Asthma Clin. Immunol. 6(1), 22 (2010).
21. Wahn V, Aberer W, Eberl W et al. Hereditary angioedema (HAE) in children and adolescents-A consensus on therapeutic strategies. Eur. J. Pediatr. 171(9), 1339-1348 (2012).
22. Caballero T, Farkas H, Bouillet L et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J. Allergy Clin. Immunol. 129(2), 308-320 (2012).
23. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-Term survey of 118 patients. Ann. Allergy Asthma Immunol. 100(2), 153-161 (2008).
24. Cruden NL, Newby DE. Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opin. Pharmacother. 9(13), 2383-2390 (2008).
25. Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin. Biol. Ther. 8(8), 1187-1199 (2008).
26. Berinert® (summary of product characteristics). CSL Behring, Marburg, Germany November 2013. www.medicines.org.uk/emc/medicine/21650/SPC/berinert
27. Cinryze® (summary of product characteristics). ViroPharma Inc., Exton, PA, USA (October 2012). www.medicines.org.uk/emc/medicine/25634/SPC/ Cinryze +500+Units+powder+and+solvent+for+solution+for+ injection
28. Ruconest® (summary of product characteristics). Pharming NV, Leiden, The Netherlands (July 2013). www.medicines.org.uk/EMC/medicine/24632/SPC/Rucone st+2100+U+powder+for+solution+for+injection
29. Firazyr® (summary of product characteristics). Shire, Basingstoke, UK (October 2013). www.medicines.org.uk/emc/medicine/21761/SPC/Firazyr+3 0+mg+solution+for+injection+in+pre-filled+syringe
30. CSL Behring Receives European Health Authorities' Approval of Berinert® for short-Term prophylaxis in adults and children. www.cslbehring.com/newsroom/Berinert-Wins-EMA-Approval-for-Short-Term-Prophy- Label?tabSelections=12559 23338674¤tPage=1
31. Berinert® (prescribing information). CSL Behring, Marburg, Germany; July 2012. http://labeling.cslbehring.com/PI/US/Berinert/EN/ Berinert-Prescribing-Information.pdf
32. Cinryze® (prescribing information). ViroPharma Biologics, Inc., Exton, PA (November 2012). www.cinryze.com/pdfs/cinryze-prescribing-information. pdf
33. Kalbitor® (prescribing information). Dyax Corp., MA, USA (February 2012). www.kalbitor.com/hcp/rems/pdf/ KalbitorFullPrescribingInformation.pdf
34. Firazyr® (prescribing information). Shire, Basingstoke, UK (August 2013). http://pi.shirecontent.com/PI/PDFs/Firazyr-USA-ENG. pdf
35. Bantia S, Zhang J, Wilson R et al. BCX4161, a small molecule orally bioavailable plasma kallikrein inhibitor for the treatment of hereditary angioedema. Presented at: Proceedings of the Annual Meeting of the American Academy of Allergy, Asthma and Immunology 2013. TX, USA, 22-26 February 2013 (Abstract P756).
36. BioCryst initiates OPuS-1: A Phase 2a Clinical Trial of BCX4161 in patients with hereditary angioedema. http://investor.shareholder.com/biocryst/ releasedetail. cfm?ReleaseID=805452
37. Sexton D, Faucette R, Viswanathan M et al. Discovery and characterization of a fully human monoclonal antibody inhibitor of plasma kallikrein for the treatment of plasma kallikrein-mediated edema. J. Allergy Clin. Immunol. 131(Suppl. 2) AB32 (2013)
38. Martinez-Saguer I, Cicardi M, Suffritti C et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: The PASSION study. Transfusion doi:10.1111/trf.12501 (2013) (Epub ahead of print).
39. A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route. http://clinicaltrials.gov/ct2/ show/NCT01576523
40. A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema. http://clinicaltrials.gov/ct2/show/NCT01912456
41. ViroPharma Incorporated reports third quarter 2013 financial results. http://ir.viropharma.com/releasedetail. cfm?ReleaseID=803048
42. R&D briefing December 2013. www.csl.com.au/investors/briefings- presentations/ operational-briefing.htm
43. Nielsen EW and Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand. 50(1), 120-122 (2006).
44. Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema. http://clinicaltrials.gov/ show/NCT01843530
45. Brackertz D, Kueppers F. Hereditary angioneurotic oedema. Lancet 2(7830), 680 (1973).
46. Gröner A, Nowak T, Schafer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 52(10), 2104-2112 (2012).
47. Feussner A, Kalina U, Machnig T, Kreuz W, Craig TJ. Biochemical Comparison of 4 Commercially available C1 estarase inhibitor concentrates for treatment of Hereditary Angioedema. Presented at: Proceedings of the European Academy of Allergy and Clinical Immunology & World Allergy Organization Allergy and Asthma Congress 2013. Milan, Italy, 22-26 June 2013 (Abstract P237).
48. Over J, Kramer C, Koendermann A, Wouters D, Zeerleder S. C1-inhibitor. In: Production of Plasma Proteins for Therapeutic Use (1st Edition). Bertolini J, Goss N, Curling J (Eds). John Wiley & Sons, Inc., NJ, USA, 241-258 (2013).
49. Joseph K, Tholanikunnel TE, Kaplan AP. Treatment of episodes of hereditary angioedema with C1 inhibitor: Serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann. Allergy Asthma Immunol. 104(1), 50-54 (2010).
50. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Von Hentig N, Klingebiel T, Kreuz W. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: A prospective study. Transfusion 50(2), 354-360 (2010).
51. Martinez-Saguer I, Müller W, Aygören-Pürsün E, Rusicke E, Stoll H, Klarmann D. Pharmacokinetic parameters of C1-inhibitor concentrate in 40 patients with hereditary angio-oedema (HAE)-A prospective study. Haemophilia 8, 574 (2002).
52. Bernstein JA, Ritchie B, Levy RJ et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann. Allergy Asthma Immunol. 105(2), 149-154 (2010).
53. Hofstra JJ, Kleine Budde I, Van Twuyver E et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®). multicenter Phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin. Immunol. 142(3), 280-290 (2012).
54. Bork K, Steffensen I, Machnig T. Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature review. Allergy Asthma Proc. 34(4), 312-327 (2013).
55. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45(11), 1774-1784 (2005).
56. Farkas H, Jakab L, Temesszentandrasi G et al. Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy. J. Allergy Clin. Immunol. 120(4), 941-947 (2007).
57. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 63(6), 751-757 (2008).
58. Craig TJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J. Allergy Clin. Immunol. 124(4), 801-808 (2009).
59. Craig TJ, Bewtra AK, Bahna SL et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy 66(12), 1604-1611 (2011).
60. Farkas H, Csuka D, Zotter Z et al. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J. Allergy Clin. Immunol. 131(3), 909-911 (2012).
61. Czaller I, Visy B, Csuka D, Fust G, Toth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: A long-Term survey. Eur. J. Obstet. Gynecol. Reprod. Biol. 152(1), 44-49 (2010).
62. Bygum A, Andersen KE, Mikkelsen CS. Self-Administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur. J. Dermatol. 19(2), 147-151 (2009).
63. Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Heller C, Klingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 52(1), 100-107 (2012).
64. Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med. 363(6), 513-522 (2010).
65. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med. 363(6), 532-541 (2010).
66. Lumry WR, Li HH, Levy RJ et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema. the FAST-3 trial. Ann. Allergy Asthma Immunol. 107(6), 529-537 (2011).
67. Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J. Allergy Clin. Immunol. 126(4), 821-827.e814 (2010).
68. Craig TJ, Bewtra AK, Hurewitz D et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc. 33(4), 354-361 (2012).
69. Craig TJ, Rojavin MA, Machnig T, Keinecke HO, Bernstein JA. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann. Allergy Asthma Immunol. 111(3), 211-215 (2013).
70. Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: A retrospective study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 112(1), 58-64 (2011).
71. Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Klingebiel T, Kreuz W. Short-Term prophylaxis with C1-inhibitor concentrate in patients with hereditary angioedema prior to surgical procedures. J. Allergy Clin. Immunol. 125(Suppl.), AB164 (2010) (Abstract 643).
72. Farkas H, Zotter Z, Csuka D et al. Short-Term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor-A long-Term survey. Allergy 67(12), 1586-1593 (2012).
73. Bork K, Hardt J. Hereditary angioedema: Long-Term treatment with one or more injections of C1 inhibitor concentrate per week. Int. Arch. Allergy Immunol. 154(1), 81-88 (2011).
74. Martinez-Saguer I, Kreuz W. Hereditary angioedema attacks in a newborn: A case of recurrent erythema marginatum. Presented at: Proceedings of the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Baltimore, MD, USA, 7-11 November, 2013 (Abstract P227).
75. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N. Engl. J. Med. 363(6), 523-531 (2010).
76. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 119(6), 1497-1503 (2007).
77. Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert. http://clinicaltrials.gov/show/NCT01467947
78. Bork K, Korger G, Kreuz W. Review of the long-Term safety of a human pasteurized C1 inhibitor concentrate. Presented at: Proceedings of the Annual Meeting of the American Academy of Allergy, Asthma and Immunology. Orlando, FL, USA, 2-6 March 2012 (Poster Number 836).
79. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: Investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32(10), 902-909 (2012).
80. Herzog E, Schuermann D, Raquet E, Zollner S, Machnig T, Pragst I. Berinert (CI-esterase inhibitor concentrate) treatment is not associated with prothrombic risk based on preclinical efficacy amd safety investigations. Presented at: Proceedings of the Annual Meeting of the American Academy of Allergy, Asthma and Immunology 2013. San Antonio, TX, USA. J. Allergy Clin. Immunol. 131(2 Suppl.), AB109 (2013).
81. CSL Behring receives European health authorities' approval of Berinert® for short-Term prophylaxis in adults and children. www.cslbehring.com/newsroom/Berinert-Wins-EMA-Approval-for-Short-Term-Prophy- Label?tabSelections=12559 23338674¤tPage=1
82. CSL Behring Receives European Health Authorities' Approval for Self-Administration of Berinert®. www.cslbehring.com/s1/cs/enco/ 1255923338532/ news/1255927105819/prdetail.htm?tabSelections=12559233 38570¤tPage=2
83. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-Administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema. www.cslbehring-us.com/s1/cs/enus/1199978939073/ news/1255927936294/ prdetail.htm
84. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-Term management of hereditary angioedema. Ann. Allergy Asthma Immunol. 104(4), 314-320 (2010).
85. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proceedings 31, 407-414 (2010).
86. Caballero T, Sala-Cunill A, Cancian M et al. Current status of implementation of self-Administration training in various regions of Europe, Canada and the USA in the management of hereditary angioedema. Int. Arch. Allergy Immunol. 161(Suppl. 1), 10-16 (2013).
87. Jolles S, Machnig T, Zbrozek A. Comparison of costs for on demand treatment of hereditary angioedema symptoms in the United Kingdom. Presented at: Proceedings of the European Academy of Allergy and Clinical Immunology & World Allergy Organization Allergy and Asthma Congress 2013. Milan, Italy, 2013 (Abstract P634).